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Introduction
From its origins in the 16th century, microscopy has
allowed the cell, as the basic unit of eukaryotic life and
disease, to be identified and analyzed. Today, quantitative
cytometric technologies, either microscope based or flow
cytometric, are the most powerful tools to analyze the pro-
liferation, physiology and differentiation of cells generally,
and are particularly useful in immunopathology. In combi-
nation with monoclonal antibodies (which recognize spe-
cific gene products) conjugated to sensitive fluorescent
dyes, cell types can be identified according to the genes
they express. They can also be isolated using either fluo-
rescence-activated cell sorting (FACS) or magnetic cell
sorting (MACS). In the past 20 years, immunofluores-
cence-based cytometry and cell sorting have become ‘state
of the art’ technologies, mostly serving to identify subsets
of lymphocytes and systemic changes in the immune
system. Although it is certainly of value for diagnosis and
analysis of immunopathology, cytometry did have one
major limitation; except in a few experimental situations,
it was not possible to focus analysis on those lymphocytes
that specifically recognize the relevant antigens in a
normal or pathological immune reaction. This drawback
has recently been overcome both for B and T lympho-
cytes, using antigen to identify the cells. Today, a number
of exciting new technologies make it possible to analyze
and isolate specifically those lymphocytes that are directly
involved in the immune reaction to given antigens. These
advances will spur research in arthritis considerably.
Why did this take so long? The problem is twofold. First,
the diversity of the immune system means that lympho-
cytes recognizing a particular antigen are rare. Estimations
of the frequencies of cells specific for one antigen used to
range from 10–5 to 10–6, based for example on limiting dilu-
tion analyses. For a number of biological and physical
reasons immunofluorescence, either with antigens or anti-
bodies, shows considerable variation in intensity. This
makes it technically difficult to identify accurately rare cells
of interest at frequencies below 10–3 to 10–4. Apart from that
basic limitation, it is extremely time consuming to analyze a
sufficient number of rare cells to obtain a reliable result.
Nevertheless, experimental work [1–4] has shown that it is
possible cytometrically to identify and analyze B memory
lymphocytes and plasma cells that occur at very low fre-
quencies and that recognize a particular antigen with high
affinity, using native antigens conjugated to haptens or
fluorochromes. The decisive technological advance in
those experiments was the use of a ‘parallel’ cell-sorting
technology (MACS), providing a nonoptical (in this case
magnetic) label to enrich antigen-binding cells to make
them detectable by flow cytometry and to isolate them for
proof of specificity. Today, the cytometry of B lympho-
cytes according to antigen specificity is not so much a
problem of technology as of biology, because B cells that
bind to one particular antigen often occur at frequencies of
1–10/ml blood, thus making the availability of sufficient
blood for analysis a limiting factor.
A second challenge for antigen-specific cytometry has
been the fact that the antigen receptors of T lymphocytes
recognize fragments of antigen only in the context of
either major histocompatibility complex (MHC) class I or
class II molecules. Initial attemps to use recombinant and
labelled MHC molecules, and to load them with peptides
of interest to stain peptide-specific T cells failed in the
late 1980s. Recently, not only has the direct labelling ofArthritis Research    Vol 1 No 1 Thiel and Radbruch
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T cells with MHC–peptide complexes finally been
achieved, but also alternative technologies have been
developed that identify T cells that react to particular
antigens by DNA synthesis, proliferation or cytokine
expression. In combination or alone, those technologies
now offer unique options to analyze antigen-specific T
lymphocytes directly ex vivo, and to isolate them for mole-
cular and functional studies. Innovative diagnostic and
therapeutic strategies based on the identification and iso-
lation of antigen-reactive lymphocytes can now be devel-
oped, targeted at the smallest functional unit of
immunological disease: the cell. These technologies will
have a profound impact not only in arthritis research, but
also on research of numerous other diseases.
Peptide–major histocompatibility complex
multimers
In 1996, Altman et al [5] were the first to show that
tetramers of peptide–MHC class I (HLA-A2) complexes
can label cytotoxic T cells specifically, providing sufficient
avidity to obtain a clearcut cytometric signal (Fig. 1). The
advance over previous attempts was the introduction of
biotin groups at the C-terminal of the recombinant MHC
molecules, allowing four-peptide–MHC monomers to be
complexed with avidin, which happens to have four
binding sites for biotin. As the authors state in their
abstract, ‘This approach should be useful in the analysis of
T cells specific for … autoantigens’. This seems very true,
although no studies have been published to date that use
tetramer technology for the analysis of autoimmune dis-
eases. One reason might be that tetramer technology
requires recombinant MHC molecules and defined pep-
tides. Although some MHC class I molecules are already
available (most notably HLA-B27 [6]), the selection is still
sparse, and is even more so for MHC class II tetramers,
which would allow identification of T helper lymphocytes.
Also, a relevant peptide has to be known beforehand (eg
from analysis of specificities of T cells expanded in vitro),
information that is not available for many autoantigens. It
is clear, however, that MHC multimers for most MHC
haplotypes will be developed soon, which will make this
technology the method of choice for the direct identifica-
tion of T cells according to their peptide specificity and
MHC restriction. Relevant peptides can be easily defined
by functional assays directly ex vivo, as described below.
Already, the available tetramers have provided extensive
data on the frequencies and phenotypes of specific T cells
for peptides from human immunodeficiency virus,
influenza virus, Epstein–Barr virus (EBV) and hepatitis C
virus, and for peptides from melanoma antigens [5,7–10].
This has shown that previous estimates based on ex-vivo
expansion of virus-reactive T cells by limiting dilution had
underestimated the frequencies of specific T cells by at
least 10-fold. For example, Callan et al [7] showed that,
during acute EBV infection, CD8+ T cells specific for a
single EBV epitope are actually not rare at all, but can com-
prise up to 44% of the total CD8+ cells in peripheral blood.
The vigorous T cell activation in antiviral immune
responses thus seems to be antigen-specific, and not driven
by bystander activations, as had been speculated earlier.
For the analysis of autoimmunity, the application of the
tetramer technology provides a few additional challenges.
One is epitope spreading (ie the sequential involvement
of additional peptide epitopes during the course of
disease). The simultaneous assessment of MHC multi-
mers with different peptides, which would be required to
analyse an array of peptides, may be limited by competi-
tion for the same T-cell receptors and the fact that current
flow cytometers can analyze four fluorescent colours per
cell maximally only. It can only be hoped that future
development of instruments will take up the challenge
and make more parameters available. That this is possible
has been demonstrated by Bigos et al [11], who provided
up to 11 parameters in their experimental setup. Future
instruments may also provide better resolution for analysis
of the cells identified by peptide–MHC multimer staining
for phenotype and function. This is the important infor-
mation. In view of the present limitations of the tetramer
technology, a number of alternative strategies have been
developed, all of which convert the reaction of T cells to
antigen into a cytometric readout. Although information is
lost about the cells that bind to the antigen but do not
react to it, these technologies offer the decisive advantage
that physiological or pathological reactions can be studied
on the level of individual cells, directly ex vivo, for
complex antigens and for any MHC haplotype restriction.
Figure 1
T-cell staining with peptide–major histocompatibility complex (MHC)
multimers. (a) Specific cells can be labeled directly ex vivo. (b) The
peptide–MHC multimer consists of a complex of four
peptide–MHC–biotin monomers complexed with avidin and directly
conjugated to fluorescein. Counterstaining for CD3 helps to ensure
specificity of the staining, but can be replaced for any other parameter
(eg secreted cytokines; see Fig. 5).27
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T-cell reactions I
DNA synthesis (bromodeoxyuridine incorporation) 
Classically, and at the level of bulk cell populations, the
reaction of a few T cells within populations has been (and
in many laboratories still is) measured by their incorpora-
tion of radioactively labelled [3H]-thymidine into DNA
during DNA synthesis, which is triggered by the antigen
from antigen-presenting cells. [3H]-thymidine incorpora-
tion is often mistaken as a measure for proliferation,
although it actually measures DNA synthesis. [3H]-thymi-
dine incorporation has a number of severe limitations,
such as lack of sensitivity caused by the low frequency of
responsive cells, and background DNA sythesis in other
cells. Also, it does not provide information on the frequen-
cies of responding cells, or on the intensity of DNA syn-
thesis per cell or its phenotype, nor does it allow isolation
of such cells for further analysis.
Flow cytometric analysis of DNA synthesis provides a
number of advantages. For instance, cells that react to
antigenic challenge by DNA synthesis can be identified
according to incorporation of bromodeoxyuridine into the
DNA [12,13]. Cells with bromodeoxyuridine-containing
DNA can then be detected with bromodeoxyuridine-spe-
cific fluorescent antibodies (Fig. 2). This technology
requires fixation of the cells, however, and thus does not
allow further functional studies. The cells can be isolated
by FACS for molecular analysis though, and their cyto-
metric analysis directly provides information on frequency
and phenotype, and allows analysis of functional mole-
cules such as intracellular cytokines.
Proliferation (carboxyfluorescein)
Cytometry offers a unique option to directly analyze pro-
liferation of cells in response to an antigenic challenge.
Cells are labelled with carboxyfluoresceine-diacetate–suc-
cinimidylester (CFDA-SE), which binds at random to sec-
ondary amino groups of cellular proteins. This provides a
uniform fluorescent label to all cells before the antigenic
challenge. Cells reacting to the antigen by proliferation
will lose 50% of their fluorescent label upon each cell divi-
sion (Fig. 3) [14]. This allows not only identification and
enumeration of antigen-reactive cells, but also supplies
information on the proliferative history of each of the
cells. Moreover, the cells can be isolated intact for func-
tional studies and molecular analysis. Needless to say,
CFDA-SE staining can be combined with stainings for
phenotype and effector molecules, such as cytokines. In
immune responses to Candida antigens, the CFDA-SE
technology compared favourably with the classical [3H]-
thymidine uptake assay [15]. An intrinsic limitation of the
CFDA-SE technology is that cells are not identified that
react with effector function rather than with proliferation,
or that die by apoptosis during the time of analysis, which
is a legitimate reaction of T cells to antigenic challenge.
Intracellular cytokine expression
Apart from DNA synthesis and proliferation, the reaction
of T cells to antigen is reflected by calcium influx, a
change in membrane potential and by the expression of
genes that respond to activation or that are required for
effector functions. Although the biochemical changes
occur fastest, their analysis in cytometry has been ham-
pered by the fact that current technologies provide too
little resolution to identify responding cells accurately if
they are rare. The situation is different for activation-
induced gene expression, in which cytokines have drawn
most attention. In T cells, their expression is transient and
depends on antigenic challenge. Although induction of
Figure 2
Cytometric analysis of DNA synthesis. (a) During antigenic challenge
ex vivo (2–5 days) bromodeoxyuridine is incorporated into the DNA of
cells performing DNA synthesis. (b) Fixed cells are stained
intracellularly with fluorescent antibodies that recognizing
bromodeoxyuridine-containing DNA.
Figure 3
Cytometric analysis of cell proliferation. (a) Cells are labelled with
carboxyfluoresceine (carboxyfluoresceine-diacetate-succinimidylester)
before antigenic challenge ex vivo (2–5 days). Cells reacting to the
antigen by proliferation will divide their fluorescent label among their
daughter cells on each cell division. (b) Carboxyfluoresceine is directly
analyzed on viable or fixed cells, and cells can be counterstained for
any other parameter.their expression is dependent on specific costimulatory
signals and DNA synthesis [16], the expression of
cytokines upon restimulation of the T cell is dependent
on antigenic challenge, and is independent of the induc-
ing costimuli and occurs with fast, uniform kinetics within
5–10h. Cytokines provide a direct measure of the effector
function of T lymphocytes. The only disadvantage for
cytometric analysis has been that they are secreted, but
are not cell surface bound, at least not abundantly, and
thus are not readily available for antibody staining of
viable cells [17]. Only recently have technologies been
developed for the cytometry of secreted proteins of viable
cells (Secretion of cytokines, below). Currently, the preva-
lent approach is the immunofluorescent staining of
cytokines within fixed cells before secretion.
For the detection of antigen-reactive T cells, intracellular
cytokine staining has been pioneered by Suni et al [18].
They have developed the technology into a whole-blood
assay, adding antigen and CD28 costimulation for a few
hours, then lysing red blood cells and staining the lympho-
cytes for intracellular cytokines and the fast activation
marker CD69 (Fig. 4). The short activation period and the
use of CD69 efficiently reduce background (staining) and
exclude bystander cells from the analysis. The efficient use
of autologous antigen-presenting cells, supported by CD28,
allows analysis either of antigens that have to be processed
or of peptides of antigens that may replace endogenous
peptides on MHC molecules of any cell. In fact, the tech-
nology has been used to identify the dominant T-cell epi-
topes of cytomegalovirus from a peptide library, as
recognized by T cells that express interferon-g upon chal-
lenge, directly ex vivo [19], and in a similar way to identify
the major autoepitopes recognized by nucleosome-specific
T cells in human systemic lupus erythematosus [20]. Cur-
rently, candidate autoantigens are evaluated by this direct
cytometric analysis of antigen-specific T cells in autoim-
mune diseases such as systemic lupus erythematodes, reac-
tive arthritis and rheumatoid arthritis.
Secretion of cytokines
The immunofluorescent detection of cytokines within T
cells before secretion requires fixation of the cells and per-
meabilization of their membranes, usually by saponin, in
order to get the staining antibodies inside the cell. This
has the obvious disadvantage that the cell is killed and the
less obvious disadvantage that the cell can no longer be
sorted by MACS technology. The additional magnetic
parameter provides essential discriminatory resolution for
the identification of cells at frequencies below 10–5 to 10–4,
and T cells reactive to many antigens are less frequent
than this. It is also required for their isolation by combined
MACS and FACS.
For the cytometry of viable cells according to proteins
secreted by them, and their availability for MACS, our
group developed cell-surface affinity matrix technology
[21]. This technology has been employed successfully in
cytometric identification, analysis and isolation of plasma
cells secreting antibodies specific for a particular antigen
[3]. For the detection of secreted cytokines and in its most
advanced version, the technology uses conjugates of anti-
bodies specific for a cell-surface protein (CD45) to anti-
bodies specific for a given cytokine (eg interferon-g). Cells
are labelled with the bispecific conjugate, allowed to
secrete cytokines and are then stained for cytokines
bound to the bispecific conjugates (Fig. 5). Initially used
in experimental set-ups for murine T cells, the cellular
affinity matrix technology has recently, and with success,
been applied to the direct ex vivo analysis of human cyto-
toxic and helper T lymphocytes that react to tetanus,
influenza and cytomegalovirus antigens by secretion of
interferon-g (Brosterhus H et al, personal communication,
1999). In many cases, magnetic cell sorting proved to be
essential for the clearcut identification of reactive cells,
because they occurred at frequencies of below 10–5 among
peripheral blood cells. Moreover, isolation of interferon-g-
secreting CD8+ Tcells helped to demonstrate that those
cells specifically killed target cells that displayed the anti-
genic peptide.
Conclusion
In terms of arthritis research, the emerging technologies
for the cytometric identification, analysis and direct isola-
tion of B and T cells binding or reacting to defined anti-
gens have provided exciting and valuable tools in our
quest to identify the role of pathogens and autoantigens in
the pathogenesis of rheumatic diseases. Most promising
appears to be a combination of the tetramer- and cytokine-
secretion technologies, allowing simultaneous identifica-
Arthritis Research    Vol 1 No 1 Thiel and Radbruch
28
Figure 4
Cytometric analysis of intracellular cytokine expression. (a) Cells can
be analyzed after short-term activation ex vivo (5–10 h). (b) Specifically
activated T cells are able to react with upregulation of the early
activation marker CD69 and effector functions (eg cytokine expression).
The cytometric analysis has to be performed on fixed cells with
permeabilized cell membranes to allow the staining antibodies to enter
the cell.tion of antigen-specific and antigen-reactive cells. To that
end, considerable advances will be required in both tech-
nologies, but even now they can help answer questions
that long remained unanswered.
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Cytometric analysis of secreted cytokines. (a) Cells can be analyzed
after short-term activation ex vivo (5–10 h). (b) A bispecific cytokine
affinity matrix, specific for a cytokine of choice and a cell-surface
molecule, is attached to the viable cells. During a short culture period
(15–30 min), secreted cytokines are bound and then stained with a
second cytokine-specific antibody.